There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid.
BACKGROUND The range of human milk docosahexaenoic acid ( DHA ) concentrations worldwide is much broader than the range explored in r and omized clinical trials to date . OBJECTIVE The primary objective was to determine the effect of 4 amounts of DHA supplementation on the visual acuity of formula-fed infants at 12 mo of age . Secondary objectives were to evaluate visual acuity maturation , red blood cell fatty acids , tolerance , anthropometric measures , and adverse events . DESIGN This double-masked , r and omized trial was conducted at 2 sites ( Dallas and Kansas City ) . Three hundred forty-three healthy , term , formula-fed infants were enrolled at 1 - 9 d of age and were r and omly assigned to be fed 1 of the following 4 infant formulas containing equivalent nutrient amounts , except for long-chain polyunsaturated fatty acids : control ( 0 % DHA ) , 0.32 % DHA , 0.64 % DHA , or 0.96 % DHA ; DHA-supplemented formulas also provided 0.64 % arachidonic acid .  Visual acuity was measured by visual evoked potentials in 244 infants who completed the 12-mo primary outcome examination . RESULTS Infants fed control formula had significantly poorer visual evoked potential visual acuity at 12 mo of age than did infants who received any of the DHA-supplemented formulas ( P < 0.001 ) . There were no significant differences in visual evoked potential visual acuity between the 3 amounts of DHA supplementation for either site at any age tested . CONCLUSIONS DHA supplementation of infant formula at 0.32 % of total fatty acids improves visual acuity . Higher amounts of DHA supplementation were not associated with additional improvement of visual acuity . This trial was registered at clinical trials.gov as NCT00753818
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .